Healthcare Costs Associated with Antiretroviral Adherence Among Medicaid Patients
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background The relationship of antiretroviral therapy (ART) adherence to total healthcare expenditures for Medicaid-insured people living with HIV or AIDS (PLWHA) is not well understood, especially among asymptomatic HIV-positive patients.Objective This study examined Medicaid-insured HIV-positive and AIDS-diagnosed patient groups to determine the association of ART adherence to mean monthly total healthcare expenditures in the 24-month measurement period, controlling for demographic, geographic, insurance, and clinical factors. The present study extends the existing literature by analyzing the relationship of ART adherence to total healthcare costs for asymptomatic HIV-positive patients separately from those patients with AIDS-defining conditions.Methods This retrospective study utilized claims data from Florida Medicaid claims from July 2006 through June 2011. All patients (n = 502) were HIV-positive, aged 18-64 years, non-pregnant, and ART naïve for at least 12 months prior to the measurement period. Each patient was categorized, based on medication possession ratios, as adherent (≥90 %) or non-adherent (<90 %), and were divided into two groups: HIV positive (n = 232) and AIDS diagnosed (n = 270). Generalized linear models predicted the mean monthly total expenditures for the non-adherence group versus the adherence group.Results For the HIV-positive group, the adjusted mean monthly expenditures for the non-adherent group were US$1,291; the adherent group adjusted mean monthly expenditures were US$1,926. The HIV-positive non-adherent group adjusted mean monthly expenditures were significantly less than the adherent group (-40 %, p < 0.001). However, for the AIDS-diagnosed group, there was not a statistically significant association of ART adherence to total healthcare expenditures (p = 0.29).Conclusion The results show that the relationship of ART adherence to healthcare costs is more complex than previously reported.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The total cost of non-adherence in AIDS was $30 523.62”
From Economic impact of medication non-adherence by disease groups: a systematic review (2018) · cites this paper as [62]
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Estimating log models: to transform or not to transform?
Manning, W. G., & Mullahy, J. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00086-8 · Cited by 1,790
The assessment of refill compliance using pharmacy records: Methods, validity, and applications
Steiner, J. F., & Prochazka, A. V. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00268-5 · Cited by 1,193
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America: A Meta-analysis
Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., Rachlis, B., Wu, P., Cooper, C., Thabane, L., et al. (2006) · JAMA · doi:10.1001/jama.296.6.679 · Cited by 899 · cited 3×
“Using pharmacy claims data has been found to be a valid proxy for medication consumption [17, 18].”
BackgroundResultGeneralized modeling approaches to risk adjustment of skewed outcomes data
Manning, W. G., Basu, A., & Mullahy, J. (2005) · Journal of Health Economics · doi:10.1016/j.jhealeco.2004.09.011 · Cited by 760
Thompson, M. A., Aberg, J. A., Cahn, P., Montaner, J. S. G., Rizzardini, G., Telenti, A., Gatell, J. M., Günthard, H. F., Hammer, S. M., Hirsch, M. S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1004 · Cited by 722
Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., Caputo, S. L., Narciso, P., Pauluzzi, S., Carosi, G., et al. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200112150-00006 · Cited by 473
Nachega, J. B., Hislop, M., Dowdy, D. W., Lo, M., Omer, S. B., Regensberg, L., Chaisson, R. E., & Maartens, G. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000225015.43266.46 · Cited by 270
Bozzette, S. A., Joyce, G., McCaffrey, D. F., Leibowitz, A. A., Morton, S. C., Berry, S. H., Rastegar, A., Timberlake, D., Shapiro, M. F., & Goldman, D. P. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441107 · Cited by 265
Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., Arici, C., Airoldi, M., & Suter, F. (2005) · Clinical Infectious Diseases · doi:10.1086/426595 · Cited by 224
Thirty Years of HIV and AIDS: Future Challenges and Opportunities
Dieffenbach, C. W., & Fauci, A. S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-11-201106070-00345 · Cited by 190
Reynolds, S. J., Makumbi, F., Nakigozi, G., Kagaayi, J., Gray, R. H., Wawer, M., Quinn, T. C., & Serwadda, D. (2011) · AIDS · doi:10.1097/qad.0b013e3283437c2b · Cited by 189
Wohl, D. A., McComsey, G., Tebas, P., Brown, T. T., Glesby, M. J., Reeds, D., Shikuma, C., Mulligan, K., Dube, M., Wininger, D., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507333 · Cited by 162
A medication self-management program to improve adherence to HIV therapy regimens
Smith, S. R., Rublein, J. C., Marcus, C., Brock, T. P., & Chesney, M. A. (2003) · Patient Education and Counseling · doi:10.1016/s0738-3991(02)00127-1 · Cited by 123 · cited 2×
“MPRs below a minimum threshold can lead to viral breakthrough or emergence of drug-resistant strains [15, 19].”
BackgroundAssociation of Antiretroviral Therapy Adherence and Health Care Costs
Nachega, J. B., Leisegang, R., Bishai, D., Nguyen, H., Hislop, M., Cleary, S., Regensberg, L., & Maartens, G. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-1-201001050-00006 · Cited by 73
Churn, churn, churn: how instability of health insurance shapes America's uninsured problem.
Short, P. F., Graefe, D. R., & Schoen, C. (2003) · PubMed · Cited by 71
Johnson, M. O., Dilworth, S. E., Taylor, J. M., & Neilands, T. B. (2011) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9230-4 · Cited by 69
Schultz, H. W. (1981) · Springer eBooks · doi:10.1007/978-94-011-7373-5_34 · Cited by 49
Gardner, E. M., Maravi, M. E., RIETMEIJER, C. A. M., Davidson, A. J., & Burman, W. J. (2008) · Applied Health Economics and Health Policy · doi:10.1007/bf03256129 · Cited by 43
Hall, A. G., Harman, J. S., & Zhang, J. (2008) · Medical Care · doi:10.1097/mlr.0b013e31817d695c · Cited by 40
Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies
Rudorf, D. C., & Krikorian, S. A. (2005) · Journal of Pharmacy Practice · doi:10.1177/0897190005278510 · Cited by 21
Harman, J. S., Hall, A. G., & Zhang, J. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.1.49 · Cited by 21
Acúrcio, F. D. A., Puig‐Junoy, J., Bonolo, P. D. F., Ceccato, M. D. G. B., & Guimarães, M. D. C. (2006) · Revista Española de Salud Pública · doi:10.1590/s1135-57272006000100005 · Cited by 21
McMahon, D. K., DiNubile, M. J., Meibohm, A. R., Marino, D. R., Robertson, M. N., & for the Protocol 060 Study Group (2007) · HIV Clinical Trials · doi:10.1310/hct0805-269 · Cited by 11
Comorbidity-Based Payment Methodology for Medicaid Enrollees with HIV/AIDS
Fakhraei, S. H., Kaelin, J. J., & Conviser, R. (2001) · PubMed · doi:10.13016/m2zpvu-qi26 · Cited by 6
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
“The total cost of non-adherence in AIDS was $30 523.(62) All studies used comparable indicators (total cost, inpatient cost, outpatient cost, pharmacy cost) to determine the cost of non-adherence.”
BackgroundKangethe, A., Polson, M., Lord, T. C., Evangelatos, T., & Oglesby, A. K. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.1.088 · Cited by 33
Abara, W. E., Adekeye, O. A., Xu, J., Heiman, H. J., & Rust, G. S. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1325-x · Cited by 28
Hellinger, F. J. (2015) · Health Affairs · doi:10.1377/hlthaff.2015.0718 · Cited by 13
Lipira, L. E., Williams, E. C., Hutcheson, R., & Katz, A. B. (2017) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2017.0112 · Cited by 5
Metadata
- Authors
- Pruitt, Z., Robst, J., Langland-Orban, B., & Brooks, R. G.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Pruitt, Zachary
- Venue
- Applied Health Economics and Health Policy
- Published
- 2014-11-18
- Volume
- 13
- Issue
- 1
- Pages
- 69-80
- ISSN
- 1175-5652 (ISSN-L)
- 1179-1896
- OpenAlex
- W1967461658
- Cited by
- 11
- References
- 27
- Citations by year
- 2024: 2 · 2023: 1 · 2020: 2 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Applied Health Economics and Health Policy (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- antiretroviral therapy adherence, health care costs, Medicaid, HIV, AIDS, asymptomatic HIV infection, medication possession ratio, health care expenditure
- MeSH terms
- Acquired Immunodeficiency Syndrome, Adolescent, Adult, Health Expenditures, Female, Florida, Humans, Male, Medicaid, Middle Aged, Retrospective Studies, United States, HIV Infections, Linear Models, Drug Monitoring, Health Care Costs, Anti-Retroviral Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.